Sessions/Tracks

ConferenceSeries Ltd invites all the participants from all over the world to attend 5th International Conference on Cancer Genomics during August 8-9, 2016 in Las Vegas, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. 

Track:1 Cancer Nanotheranostics

Theranostics – a combination of the words therapeutics and diagnostics – describes a treatment platform that combines a diagnostic test with targeted therapy based on the test results, i.e. a step towards personalized medicine. Making use of nanotechnology materials and applications, theranostic nanomedicine can be understood as an integrated nanotherapeutic system, which can diagnose, deliver targeted cancer therapy and monitor the response to therapy.

Related Conferences:

5th World Congress on Cancer Therapy, September 28-30, 2015 Atlanta, Georgia, USA, International Conference on Molecular and Cancer Biomarkers September 15-17, 2016 Berlin, Germany ; 10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany; 13th International Conference on Nanotek and Expo December 05-07, 2016 Seattle, USA, International Conference on Nano medicine, Drug Delivery, and Tissue Engineering (NDDTE'16), April 1 - 2, 2016, Prague, Czech Republic; MEDICON 2016, March 31- April 2, 2016 Paphos, Cyprus; 4th International Conference on Advanced Nanomaterial and Nanotechnology, Dec 8-11, 2015, Guwahati, India; NIPS 2016, December 4 - 9, 2016, Barcelona, Spain; 18th International Conference on Nanoscience, Nanotechnology and Engineering, September 29 - 30, 2016, London, United Kingdom

Track: 2 Whole Genome Sequencing

Whole genome sequencing also known as full genome sequencing, complete genome sequencing, or entire genome sequencing is a laboratory process that determines the complete DNA sequence of an organism's genome at a single time.

Related Conferences:

International Conference on Clinical and Molecular Genetics, November 28-30, 2016 Chicago, USA; 2nd International Conference on Transcriptomics August 18-20, 2016 Portland, Oregon USA; International Conference on Next Generation Sequencing July 21-22, 2016 Berlin, Germany; The Fourteenth Asia Pacific Bioinformatics Conference, 11th-13 January 2016, San Francisco, USA; World Congress on Human Genetics October 31- November 02, 2016 Valencia, Spain; 18th International Conference on Genetics and Genomics, June 9 - 10, 2016, San Francisco, USA; NGS ’16 Genome Annotation, April 4 – 6, 2016, Barcelona, Spain; Maintenance of Genome Stability 2016, March 7-10, 2016, Panama, Central America; Epigenomics: new marks, new horizons, December 2015, 2 December 2015, UK; Human Genome Meeting, 28 February – 2 March 2016, Houston, USA

Track: 3 Stem cells- Cancer

One of the most exciting recent developments in the field of cancer biology is the recognition that lineage progression continues to occur in tumours. In particular, there is an increasing body of evidence that like normaltissues, tumor cells that have the potential for unlimited self-renewal give rise in large numbers to cells that lack this potential - the so-called cancer stem cell hypothesis. By focusing for so many years on the majority cell populations in tumors, and not on the rarer cancer stem cells (cancer initiating cells), scientists and clinicians may have missed out on opportunities to understand, diagnose and treat the processes in cancer that matter most.

Related Conferences:

International Conference on Pancreatic and Colorectal Cancer, March 29-30, 2016, Atlanta, USA; International Conference on Prostate Cancer and Treatment, May 5-7, 2016, Chicago, USA; Cancer Diagnostics Conference and Expo June 13-15, 2016, Rome, Italy; International Conference on Tissue Engineering and Regenerative Medicine, Sept 12-14, 2016, Berlin Germany; Gene Regulatory Networks and the Encoded Causality of Development, May 16-18, 2016, California, USA; Stem Cell Models of Neural Degeneration and Disease, February 1-3, 2016 Dresden, Germany; Stem Cells and Cancer, March 6-10, 2016, Colorado, USA; Transdifferentiation and Tissue Plasticity in Cardiovascular Rejuvenation; February 7-10, 2016, West Sussex, UK

Track: 4 Trends in Cancer Genomics

The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer- Progress in DNA sequencing has revealed the startling complexity of cancer genomes, which typically carry thousands of somatic mutations. Large-scale cancer genomics has further established a baseline that is now poised to effect the translation ofcancer genomics into the clinical setting, effectively transforming patient care. The barriers and challenges totranslation are significant, not the least of which involves the transition of research-grade computational and interpretational analysis to clinical-grade analysis.

Related Conferences:

International Conference on Cervical Cancer, 22-23 September, 2016 (Vienna, Austria); 6th World Congress on Cancer Therapy, 01-03 December, 2016 (Baltimore, USA); 13th Global Summit on Cancer Therapy 17-19 October, 2016 (Dubai, UAE); International Conference on Pancreatic and Colorectal Cancer, 29-30 March, 2016 (Atlanta, USA); Global Summit on Melanoma And Carcinoma, 14-15 July, 2016 (Brisbane, Australia); Chromatin and Epigenetic in Cancer ( Atlanta, Georgia); Advances in Ovarian Cancer Research: Exploiting Vulnerabilities (Orlando, Florida); Advance in Breast Cancer Research ( Washington, DC); Advances in Pediatric Cancer Research (Florida);  New Horizons in Cancer Research Conference (Sanghai, China).

Track: 5 Cancer Biopsy

Cancer is a heterogeneous genetic disease, and excisional biopsies provide only a snapshot in time of some of the rapid, dynamic genetic changes occurring in tumors. In addition, excisional biopsies are invasive, can’t be used repeatedly, and are ineffective in understanding the dynamics of tumor progression and metastasis. However, liquid biopsy, or blood-sample tests, under development by Epic Sciences can generate actionable information for oncologists by analyzing circulating tumor cells (CTCs) and fragments of tumor-cell DNA that are continuously shed by tumors into the bloodstream.

Related Conferences:

8th Euro Global Summit on Cancer Therapy November 03-05, 2015 Valencia, Spain; 2nd International Conference on Antimicrobial Agents and Chemotherapy June 06-07, 2016 Dallas, USA; Cancer Diagnostics Conference and Expo June 13-15, 2016 Rome, Italy;  International Conference on Molecular and Cancer Biomarkers September 15-17, 2016 Berlin, Germany; International Conference on Cervical Cancer September 22-23, 2016 Vienna, Austria;  IBCC — 1st International & 8th Annual Breast Cancer Congress Dates28 Oct - 30 Oct 2015 Location Tehran, Iran; UCC — UAE Cancer Congress 29 - 31 Oct 2015 Dubai, United Arab Emirates; 4th Cancer Epigenetics Conference Nov 16-17, 2015 San Francisco, CA, United States.

Track: 6 Cancer  Genome Therapy

Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases. These studies highlight the opportunity for strategies to achieve truly personalized cancer treatment. Particularly important has been the use of genome-scale gene expression analyses to identify discrete disease classes not previously recognized.

Related Conferences:

International Conference on Next Generation Sequencing, July 21-22, 2016 Berlin, Germany; 4th International Conference on Integrative Biology, July 18-20, 2016, Berlin, Germany, International Conference on Clinical and Molecular Genetics, November 28-30, 2016 Chicago, USA; International Conference on Molecular & Cancer Biomarkers, September 15-17 2016, Berlin, Germany; 5th International Conference on Cell and Gene Therapy, May 19-21, 2016 San Antonio, USA; Cancer Genome (Q1), February 7-11, 2016, Alberta, Canada; 18th International Conference on Cancer Genomics, January 26 - 27, 2016, Jeddah, Saudi Arabia; Enhancer Malfunction in Cancer (Q6), February 21-24, 2016, New Mexico, USA; DNA Damage, Mutation and Cancer, March 13-18, 2016, Ventura, USA; Chromatin and Epigenetics, 20 March 2016, Dubrovnik, Croatia

Track: 7 Epigenetics and cancer genomics

The field of cancer epigenetics is evolving rapidly on several fronts. Advances in our understanding of chromatin structure, histone modification, transcriptional activity and DNA methylation have resulted in an increasingly integrated view of epigenetics. In response to these insights, epigenetic therapy is expanding to include combinations of histone deacetylase inhibitors and DNA methyltransferase inhibitors.

Related Conferences:

International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016, Birmingham, UK; Biotechnology World Convention, Aug 15-17, 2016, Sao Paulo, Brazil; International Conference on Synthetic Biology, Aug 18-19, 2016, London, UK, Annual Conference on Bio Science, Sept 12-13, 2016, Berlin, Germany; Noncoding RNAs in Health and Disease, February 21-24, 2016, Santa Fe, USA; Maintenance of Genome Stability March 7- 10, 2016, Panama, South America; Chromatin and Epigenetics, March 20-24, 2016 Whistler, Canada; Chromatin, Non-Coding RNAs and RNAP II Regulation in Development and Disease, March 29, 2016, Austin, USA; Chromatin Structure and Function, May 22-27, 2016, Les Diablerets, Switzerland

Track: 8 Cancer Nanotechnology

Nanotechnology is increasingly finding use in the management of cancer. Nanoscale devices have impactedcancer biology at three levels: early detection using, for example, Nano cantilevers or nanoparticles; tumour imaging using radio contrast nanoparticles or quantum dots; and drug delivery using nanovectors and hybrid nanoparticles.

Related Conferences:

5th World Congress on Cancer Therapy, September 28-30, 2015 Atlanta, Georgia, USA, International Conference on Molecular and Cancer Biomarkers September 15-17, 2016 Berlin, Germany ; 10th Global Annual Oncologists Meeting July 11-13, 2016 Cologne, Germany; 13th International Conference on Nanotek and Expo December 05-07, 2016 Seattle, USA, International Conference on Nano medicine, Drug Delivery, and Tissue Engineering (NDDTE'16), April 1 - 2, 2016, Prague, Czech Republic; MEDICON 2016, March 31- April 2, 2016 Paphos, Cyprus; 4th International Conference on Advanced Nanomaterial and Nanotechnology, Dec 8-11, 2015, Guwahati, India; NIPS 2016, December 4 - 9, 2016, Barcelona, Spain; 18th International Conference on Nanoscience, Nanotechnology and Engineering, September 29 - 30, 2016, London, United Kingdom

Track: 9 Hormone-Dependent Cancers

Hormones influence not only breast and prostate cancer, the two most common hormone-dependent cancers, but also have a major impact on less common hormone-sensitive malignancies (e.g. ovary, testes, endometrium) as well as human cancers recently discovered to be hormone sensitive (e.g. lung, liver).

Related Conferences:

International Conference on Pancreatic and Colorectal Cancer, March 29-30, 2016, Atlanta, USA; International Conference on Prostate Cancer and Treatment, May 5-7, 2016, Chicago, USA; Cancer Diagnostics Conference and Expo June 13-15, 2016, Rome, Italy; International Conference on Tissue Engineering and Regenerative Medicine, Sept 12-14, 2016, Berlin Germany; Gene Regulatory Networks and the Encoded Causality of Development, May 16-18, 2016, California, USA; Stem Cell Models of Neural Degeneration and Disease, February 1-3, 2016 Dresden, Germany; Stem Cells and Cancer, March 6-10, 2016, Colorado, USA; Transdifferentiation and Tissue Plasticity in Cardiovascular Rejuvenation; February 7-10, 2016, West Sussex, UK
 

Track: 10 Frontiers in Gene Editing

Gene editing is rapidly progressing from being a research/ screening tool to one that promises important applications downstream in drug development, cell therapy and bioprocessing.  Genome editing  is now a new trend in 2016. The engineered editing system makes use of an enzyme that nicks together DNA with a piece ofsmall RNA that guides the tool to where researchers want to introduce cuts or other changes in the genome.

Related Conferences:

International Conference on Cervical Cancer, 22-23 September, 2016 (Vienna, Austria); 6th World Congress on Cancer Therapy, 01-03 December, 2016 (Baltimore, USA); 13th Global Summit on Cancer Therapy 17-19 October, 2016 (Dubai, UAE); International Conference on Pancreatic and Colorectal Cancer, 29-30 March, 2016 (Atlanta, USA); Global Summit on Melanoma And Carcinoma, 14-15 July, 2016 (Brisbane, Australia); Chromatin and Epigenetic in Cancer ( Atlanta, Georgia); Advances in Ovarian Cancer Research: Exploiting Vulnerabilities (Orlando, Florida); Advance in Breast Cancer Research ( Washington, DC); Advances in Pediatric Cancer Research (Florida);  New Horizons in Cancer Research Conference (Sanghai, China).

Track: 11 Big Data in Cancer Genomics  

Several recently announced collaborations between academic research institutions and big data analytics vendors powering advanced discovery technologies will bring the power of big data to new studies that may have significant impacts on future therapies and treatments.  With oncology and genomics in the spotlight,personalized medicine is poised to take a leap forward as researchers dive into complex diseases. By analysing data from multiple cancer types, we could evaluate prognostic models and identify gene alterations that led to tumor formation. This wouldn’t have been obtained by looking at tumor data from just one cancer type.

Related Conferences:

International Conference on Clinical and Molecular Genetics, November 28-30, 2016 Chicago, USA; 2nd International Conference on Transcriptomics August 18-20, 2016 Portland, Oregon USA; International Conference on Next Generation Sequencing July 21-22, 2016 Berlin, Germany; The Fourteenth Asia Pacific Bioinformatics Conference, 11th-13 January 2016, San Francisco, USA; World Congress on Human Genetics October 31- November 02, 2016 Valencia, Spain; 18th International Conference on Genetics and Genomics, June 9 - 10, 2016, San Francisco, USA; NGS ’16 Genome Annotation, April 4 – 6, 2016, Barcelona, Spain; Maintenance of Genome Stability 2016, March 7-10, 2016, Panama, Central America; Epigenomics: new marks, new horizons, December 2015, 2 December 2015, UK; Human Genome Meeting, 28 February – 2 March 2016, Houston, USA

Track: 12 Cell fate in cancer 

The cell is the basic unit of life. The attainment of a nucleus to house the genetic material is thought to have provided a distinct advantage to the evolving cell, ultimately allowing the emergence of differentiated, specialized cells.  Hoarding evidence suggests that genomes are organized non-randomly into complex 3D configurations that vary according to cell type, stage of development, differentiation and disease status. The principles, which guide higher order organization, the mechanisms responsible for establishment, maintenance and alterations of higher order genome, and the functional consequences of aberrant genome and nuclear organization, have become zones of intense interest.

Related Conferences:

8th Euro Global Summit on Cancer Therapy November 03-05, 2015 Valencia, Spain; 2nd International Conference on Antimicrobial Agents and Chemotherapy June 06-07, 2016 Dallas, USA; Cancer Diagnostics Conference and Expo June 13-15, 2016 Rome, Italy;  International Conference on Molecular and Cancer Biomarkers September 15-17, 2016 Berlin, Germany; International Conference on Cervical Cancer September 22-23, 2016 Vienna, Austria;  IBCC — 1st International & 8th Annual Breast Cancer Congress Dates28 Oct - 30 Oct 2015 Location Tehran, Iran; UCC — UAE Cancer Congress 29 - 31 Oct 2015 Dubai, United Arab Emirates; 4th Cancer Epigenetics Conference Nov 16-17, 2015 San Francisco, CA, United States.

About Conference

About Conference:

ConferenceSeries Ltd invites all the participants from all over the world to attend 5th International Conference on Cancer Genomics during August 8-9, 2016 in Las Vegas, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Cancer Genomics-2016 is an area within genomics that concerns the genetic mutations responsible for Cancer using genome sequencing and bioinformatics. The fields of Cancer Biology and Genetics are mainly concerned with the study of the role and function of single genes, a major topic in today’s biomedical research.

OMICS International organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publish 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

With members from around the world focused on learning about Cancer Genomics and its advances in Diagnosis, Treatment, Prevention; this is your best opportunity to reach the largest assemblage of participants from the Cancer Genomics and its allied areas. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Cancer Genomics are hallmarks of this conference.

Target Audience:

•   Cancer Researchers
•   Oncologists
•   Radiologists
•   Oncology Faculty
•   Genomic Students
•   Genomics Researchers
•   Genomics Faculty
•   Genomics Scientists
•   Genomics Colleges
•   Pharmacology Scientists
•   Pharmacology Health Professionals
•   Genetics Associations and Societies
•   Geneticists
•   Genetic Counselors
•   Biopharmacists
•   Business Entrepreneurs
•   Training Institutes
•   Software developing companies
•   Data Management Companies

Market Analysis

ConferenceSeries Ltd invites all the participants from all over the world to attend '5th International  Conference on Cancer Genomics' during August 8-9, 2016 in Las Vegas, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

For more details please visit:
http://cancergenomics.conferenceseries.com/

Why Las Vegas?

Las Vegas is the most populous city in Nevada, the seat of Clark County, and an internationally renowned major resort city for shopping and fine dining. Las Vegas, which bills itself as The Entertainment Capital of the World, is famous for the number of casino resorts and associated entertainment. A growing retirement and family city, it is the 28th most populous city in the United States.

The major attractions in Las Vegas are the casinos and the hotels. The most famous hotel casinos are located on Las Vegas Boulevard on the portion of that road known as the Las Vegas Strip. These larger casinos are located outside of the city. Many of these hotels are massive, providing thousands of rooms, with their large adjoining casino areas. There are many hotel casinos in the city's downtown area as well, which was the focal point of the city's gaming industry in its early days. Several large hotels and casinos are also located somewhat off the Strip, as well as in the county around the city.

Some of the most notable casinos involved in downtown gaming are on the Fremont Street Experience which was granted variances to allow bars to be closer together, similar to the Gaslamp Quarter of San Diego.

Conference Highlights:
Cancer Nanotheranostics
Whole Genome Sequencing
Stem cells- Cancer
Emerging Themes in Cancer Genomics
Cancer Biopsy
Cancer Genome Therapy
Epigenetics and cancer genomics
Cancer Nanotechnology
Hormone-Dependent Cancers
New Frontiers in Gene Editing
Big Data in Cancer Genomics
Cell fate in cancer

Why to attend???

With members from around the world focused on learning about Cancer Genomics and its advances; this is your best opportunity to reach the largest assemblage of participants from the Cancer Genomics Community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new ways of treatment & care, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Cancer Genomics are hallmarks of this conference.

Target Audience:

Genome researchers, cancer researchers, geneticists, oncologists, radiologists, biologists, health-care industrialists, leading universities, research institutions, Oncology Faculty, Medical Colleges, Cancer/Oncology Associations and Societies, Business Entrepreneurs, Training Institutes, Software developing companies, Manufacturing Medical Devices Companies, Pharmaceutical Companies and students in allied areas of Cancer and Genomics can be the target audience.

Target Audience:
Academia       70%
Industry       25%
Others          5%

Market Analysis of Cancer Genomics:

Cancer Genomics is expected to witness continued growth, owing to the increasing commercial adoption of genomic testing for various applications. The PCR segment constitutes the largest technology segment in the global market. The global cancer/tumor profiling market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018. National Institutes of Health awards total approximately $6.7 million in the first year and, if funding remains available, approximately $27 million in total.

Market Value of Cancer Therapies:

The global market for cancer therapies was worth $110.6 billion in 2013 and this should increase to over $175.6 billion by 2018, a compound annual growth rate (CAGR) of 12.6%. Although significant improvements in the diagnosis and development of various compounds to treat cancer have been made, cancer remains a major healthcare challenge worldwide.

Research Institutes and Labs associated with Cancer:

Amazon Web Services, Ltd. (US)
 American Association for Cancer Research (US)
 American College of Medical Genetics and Genomics (US)
 American Society of Clinical Oncology (US)
 American Society of Human Genetics (US)
 Amgen (US)
 Australian Genome Research Facility (AGRF) (AU)
 Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) (US)
BBMRI-NL (NL)

Statistical Analysis of Cancer Associations:

 Major Genetic Research Associations around the globe:

 Belgian Medical Genomics Initiative (BE)
 EMBL-European Bioinformatics Institute (UK)
 EMC Corporation (US)
 European Molecular Biology Laboratory (DE)
 European Society of Human Genetics (AT)
 Fitgenes Limited (AU)
 Five3 Genomics (US)
 Garvan Institute of Medical Research (AU)
GATC Biotech AG (DE)
 Geneix (UK)
 Gene stack Limited (UK)
 Genetic Alliance (US)
 Genetic Alliance UK (UK)
 Genome British Columbia (CA)
 Genome Canada (CA)
 Genome Institute of Singapore (SG)
 Human Genetics Society of Australasia (AU)
 Human Genome Organisation (SG)
 National Institute of Genomic Medicine (MX)
 New York Genome Center (US)
 Wellcome Trust Sanger Institute (UK)

Companies Associated with Cancer Genomics:
    Roche
    Novartis 
    Celgene
    Johnson & Johnson
    Bristol-Myers Squibb
    Lilly
    Amgen
    Takeda
    AstraZeneca

Past Conference Report

Genomics 2015

Conference Series LLC  hosted 3^rd International Conference on Genomics & Pharmacogenomics during September 21-23, 2015 at San Antonio, USA based on the theme “Implications & Impacts of Genomic Advances on Global Health”.

Active participation and generous response was received from the Organizing Committee Members, scientists, researchers, as well as experts from Non-government organizations, and students from diverse groups who made this conference as one of the most successful and productive events in 2015 from Conference Series LLC 

The conference was marked with several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from scientists, young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.   

The conference was initiated with a warm welcome note by Honorable guests and the Keynote forum. The proceedings went through interactive sessions and panel discussions headed by honorable Moderator Dr. Aditi Nadkarni, New York University, USA for the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted as Keynote speakers:

Utilizing cancer sequencing in the clinic - Best practices in variant analysis, filtering and annotation: Andreas Scherer, Golden Helix Inc., USA

The role of genomics in gene therapy and diagnostic testing and related intellectual property issues: Krishna Dronamraju, Foundation for Genetic Research, USA

Epigenesis, methylation, and single strand breaks: Rosemarie Wahl, St. Mary's University, USA

The application of validation and proficiency testing concepts from current clinical genetic diagnostics for the implementation of new genetic technologies: Kathleen S Wilson, U.T Southwestern Medical Center, USA

Biomimetic membranes: Mariusz Grzelakowski, Applied Biomimetic Inc., USA

The Genomics-2015 also being highlighted for the below International workshop:

Understanding the effects of steroid hormone exposure on regulation of P53 and Bcl-2 gene expression

OMICS Group has taken the privilege of felicitating Genomics-2015 Organizing Committee, Keynote Speakers who supported for the success of this event. OMICS Group, on behalf of the Organizing Committee congratulates the Best Poster awardees for their outstanding performance in the field of Genomics & Pharmacogenomics and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors.   

Poster Judging was done by: Dr. Hao Mei, University of Mississippi Medical Center, USA
Best Poster Award was received by: Mr. Juan Carlos Alberto Padilla, Instituto Politecnico Nacional, Mexico

Genomics-2015 attracted the Society for General Microbiology, UK and they came forward to advert their leading journals on the back side cover of conference proceedings book.

Genomics-2015 was sponsored by one of the leading bioinformatics solution center BGI Americas, USA

Genomics-2015 necessarily thanks Aeon Clinical Laboratories, USA for exhibiting recent innovations and express ways in clinical testing.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Genomics-2015.

With the unique feedback from the conference, OMICS Group would like to announce the commencement of the "6^th International Conference on Genomics & Pharmacogenomics, during September 12-14, 2016 at Berlin, Germany.

For More details visit:  http://genomics.conferenceseries.com/

Conference Series LLC 

The International Conference on Functional and Comparative Genomics & Pharmacogenomics (Genomics-2013) was organized by the Conference Series LLC  during November 12-14, 2013 at DoubleTree by Hilton Hotel Chicago-North Shore, IL, USA. The conference was well received with participation from Genomics-2013 Organizing Committee Members, researchers, scientists, technologists and students from various parts of the world. The three day program witnessed thought provoking speeches from experts which focused on the theme “Recent Research Methodologies and Discoveries in Genomics Era”. The theme touched upon various topics like

•    Functional and Comparative Genomics
•    Pharmacogenomics and Personalized medicine
•    Evolutionary and Developmental Genomics
•    Bioinformatics in Genomics & Proteomics
•    Cancergenomics
•    Epigenomics, Transcriptomics and Non-coding genomics
•    Genome Sequencing & Mapping
•    Plant & Ecological Genomics
•    Biomarkers & Molecular Markers

The Conference has gathered support from The European Society of Pharmacogenomics and Theranostics (ESPT), The Nestle Institute of Health Sciences and Geneticational.

Genomics-2013 has swirl up the scientific thoughts on various current genome research related areas. The conference has shown scope of pharmacogenomics (studies of how variations in the human genome affect response to the drugs) and its implications in global health and pharma industry. The conference focused on how pharmacogenomics aids in diagnosing genetic information thus helping to predict not only patient’s drug response but also many other effects like adverse drug effects and their interactions and the diseases related to that gene. The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the Keynote Forum.

Clyde A. Hutchison, Distinguished Investigator from J. Craig Venter Institute, USA who helped in determining the first complete sequence of a DNA molecule (phiX174) and developed site-directed mutagenesis with Michael Smith (1978) delivered a phenomenal and worthy keynote presentation on Building a minimal cell – The JCVI design-build-test cycle for synthetic cells during the conference.

Roger Hendrix, Distinguished Professor from University of Pittsburgh, USA explained how he and his group are involved in Genomic analysis of bacteriophages.

William C. Reinhold from National Cancer Institute, NIH, USA presented his speech on “The current state of comparative genomics and pharmacogenomics, and the application of the NCI-60 resources and CellMiner tools to these problems”.

The conference was chaired by Alexander Bolshoy, Yasuo Iwadate, Gil Atzmon, Gary A. Bulla, Jatinder Lamba, William C. Reinhold, Luciano Brocchieri and Ning-Sun Yang.

Along with the participants of Genomics-2013, we would like to express our gratitude to Dr. Alexander Bolshoy and Dr. William C. Reinhold for their extreme support and assistance towards the conference.

Students from various parts of the world took active participation in poster presentations. Mr. Aren Ewing and Mr. Chih-Yao Hsu were awarded with best posters for their outstanding contribution.

OMICS Group also took the privilege of felicitating Genomics-2013 Organizing Committee,Editorial Board Members of Journal of Data Mining in Genomics and Proteomics, Journal of Pharmacogenomics and Pharmacoproteomics, Journal of Phylogenetics and Evolutionary Biology and Journal of Proteomics and Bioinformatics, Keynote Speakers,  Chair and Co-Chairs whose support led the conference into the path of excellence.

The warm support and suggestions from all the participants, inspires us in organizing “2nd International Conference on Genomics & Pharmacogenomics” which will be held duringSeptember 08-09, 2014 Raleigh, USA.